Halozyme Therapeutics (HALO) Shares Outstanding (Diluted Average) (2010 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Shares Outstanding (Diluted Average) data on file, last reported at $122.9 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $122.9 million, down 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.9 million (down 2.98% YoY), and the FY2025 annual result was $123.9 million, down 4.27% from the prior year.
• Shares Outstanding (Diluted Average) eased to $122.9 million in Q1 2026 per HALO's latest filing, from $123.9 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $141.8 million in Q2 2022 and troughed at $122.9 million in Q1 2026.
• A 5-year average of $132.1 million and a median of $130.1 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) dropped 6.54% in 2024, then decreased 1.74% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $140.6 million in 2022, then fell by 4.56% to $134.2 million in 2023, then retreated by 3.56% to $129.4 million in 2024, then retreated by 4.27% to $123.9 million in 2025, then declined by 0.83% to $122.9 million in 2026.
• Business Quant data shows HALO's Shares Outstanding (Diluted Average) at $122.9 million in Q1 2026, $123.9 million in Q4 2025, and $124.4 million in Q3 2025.